Researchers test CRISPR-based COVID-19 therapy

A team of scientists from Stanford University have joined forces with researchers at Berkeley Lab's Molecular Foundry to test a gene-targeting, antiviral agent against COVID-19.
June 5, 2020

A team of scientists from Stanford University have joined forces with researchers at Berkeley Lab's Molecular Foundry to test a gene-targeting, antiviral agent against COVID-19.

Last year, a Stanford University team began working on a technique called PAC-MAN — or Prophylactic Antiviral CRISPR in human cells — that uses the gene-editing tool CRISPR to fight influenza. Since March, the team has been collaborating with researchers at the Biological Nanostructures Facility at Berkeley Lab's Molecular Foundry to develop a system that delivers PAC-MAN into the cells of a patient, hoping that, ultimately, PAC-MAN can neutralize the coronavirus and stop it from replicating inside cells.

In late April, the Stanford researchers tested a type of lipitoid that self-assembles with DNA and RNA into PAC-MAN carriers in a sample of human epithelial lung cells. The results were encouraging.  Next they will test the PAC-MAN/lipitoid system in an animal model against a live SARS-CoV-2 virus.

If successful, two groups hope to further develop PAC-MAN/lipitoid therapies for SARS-CoV-2 and other coronaviruses, and to explore scaling up their experiments for preclinical tests.

Read the story in Science Daily

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates